Omeros (OMER) OMS302 Could See Increased Use, Target Taken to $28 at Wedbush

September 16, 2013 10:08 AM EDT Send to a Friend
Get Alerts OMER Hot Sheet
Price: $23.13 +3.91%

Rating Summary:
    8 Buy, 0 Hold, 0 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 14 | Down: 28 | New: 51
Trade OMER Now!
Join SI Premium – FREE
Wedbush maintained an Outperform rating on Omeros Corp. (NASDAQ: OMER) and raised its price target to $28.00 (from $18.00). Analyst Liana Moussatos sees potential for increased use of OMS302.

"The FDA is cracking down on sterility of topical solutions used during intraocular lens replacement surgery. We recently had a conversation with a high-volume cataract surgeon about the changing regulatory landscape following sterility issues at compound pharmacies. The FDA has indicated that each patient must be given a separate bottle for topical NSAIDs and mydriatic agents. In addition, surgeons are no longer allowed to mix their own homebrews of these agents for use during surgery—a common practice," said Moussatos.

"The net impact is that the cost of topical NSAIDs and mydriatic agents per cataract procedure is rising—making not only the cost of OMS302 (we estimate ~$250/procedure in the U.S.) to be closer to topical agents, but also making it the only product combining pain relief and mydriasis which complies with these new regulations," she added.

For an analyst ratings summary and ratings history on Omeros Corp. (NASDAQ: OMER) click here. For more ratings news on Omeros Corp. click here.

Shares of Omeros Corp. closed at $5.09 yesterday.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Analyst Comments, Analyst EPS View, Analyst PT Change, Hot Comments

Add Your Comment